|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-17
|
|
pubmed:abstractText |
APR-246 belongs to a new generation of the compounds that restore normal p53 function in cells with mutated or wild type p53. The purpose of this study was to examine the effects of APR-246 alone and in combination with other drugs in acute myeloid leukemia (AML) cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2,2-bis(hydroxymethyl)-1-azabicyclo(...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aza Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/BAX protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bicyclo Compounds, Heterocyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p14ARF,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-2-Associated X Protein,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1600-0609
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2011 John Wiley & Sons A/S.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
206-15
|
|
pubmed:meshHeading |
pubmed-meshheading:21114538-Antineoplastic Agents,
pubmed-meshheading:21114538-Aza Compounds,
pubmed-meshheading:21114538-Base Sequence,
pubmed-meshheading:21114538-Bicyclo Compounds, Heterocyclic,
pubmed-meshheading:21114538-Cytarabine,
pubmed-meshheading:21114538-DNA Primers,
pubmed-meshheading:21114538-Daunorubicin,
pubmed-meshheading:21114538-Drug Resistance, Neoplasm,
pubmed-meshheading:21114538-Drug Synergism,
pubmed-meshheading:21114538-Female,
pubmed-meshheading:21114538-Gene Expression,
pubmed-meshheading:21114538-Genes, p53,
pubmed-meshheading:21114538-Humans,
pubmed-meshheading:21114538-Karyotyping,
pubmed-meshheading:21114538-Leukemia, Myeloid, Acute,
pubmed-meshheading:21114538-Male,
pubmed-meshheading:21114538-Mutation,
pubmed-meshheading:21114538-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:21114538-Tumor Cells, Cultured,
pubmed-meshheading:21114538-Tumor Suppressor Protein p14ARF,
pubmed-meshheading:21114538-Vidarabine,
pubmed-meshheading:21114538-bcl-2-Associated X Protein
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
|
|
pubmed:affiliation |
Hematology Centre, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
